Popular Articles
Natural Remedies

START Trial Will Show Whether Therapeutic Vaccine Stimuvax Has Potential To Extend Lung Cancer Survival Beyond Five Years
Of all cancers, non-small cell lung cancer (NSCLC) represents one of the greatest unmet needs for an effective and life-prolonging treatment. The condition, which accounts for 85 per cent of all lung cancers - roughly 1.4 million worldwide each year - is rarely diagnosed at its earliest and most potentially curable stage when it is amenable to surgical resection. Most patients are diagnosed when the tumour has already advanced to stage III, where it has invaded the chest tissues or mediastinal lymph nodes and is inoperable, or to stage IV where it has spread to other organ sites. Around 30 per cent are diagnosed at stage III and 40 per cent at stage IV. Both stages carry a poor prognosis. From stage III, and following chemo and radiotherapy treatment, median survival has been at best only between 13 and 18 months.
generic viagra online
Sen. Baucus Says Health Care Overhaul Will Cover About 95% Of Citizens, Will Not Cover Undocumented Immigrants
Senate Finance Committee Chair Max Baucus (D-Mont.) on Thursday said that Congress" health care overhaul plan would cover 94% to 96% of the population but not undocumented immigrants, the AP/Las Vegas Sun reports (Alonso-Zaldivar, AP/Las Vegas Sun, 5/21). In remarks at a briefing sponsored by the Kaiser Family Foundation, Families USA and the National Federation of Independent Business, Baucus said, "There are always going to be some people ... you just can"t find" to enroll, adding that "we"re going to try to get as close as we can (to 100% coverage) and we"re working hard to accomplish that." He added, "[W]e"re not going to cover undocumented workers. That"s too politically explosive" (Reichard, CQ HealthBeat, 5/21). According to an analysis by the Center for Immigration Studies and the U.S. Census Bureau, undocumented immigrants make up between 15% and 22% of the estimated 47 million U.S. residents without health coverage. Baucus said, "I don"t have a good answer yet to undocumented workers, illegal aliens," adding, "There will still be charity care " (Landers, Dallas Morning News, 5/22). Baucus said that the bill his committee is working on and that he expects to mark up in mid-June will include "incentives" and possibly requirements for employers to pay for employee health insurance. Baucus mentioned the possibility of including an individual mandate and establishing a health insurance exchange (AP/Las Vegas Sun, 5/21). Baucus also noted that the plan most likely will include a public health insurance option in some form (Tumulty, "Swampland," Time Magazine, 5/21). "Everything"s on the table," Baucus said, warning that "because this is so big, so complex, there are going to be a lot of trade-offs. ... This is just so large" (CQ HealthBeat, 5/21). He said that he is very optimistic about the prospects of bipartisan support for the legislation, placing the odds at between 75% and 80% ("Swampland," Time Magazine, 5/21).
News of the day
Sotomayor's Record Contradicts Conservatives' Claims Of Radicalism, Washington Post Columnist Writes
"If Sonia Sotomayor is a radical activist eager to push the law leftward or to rule according to personal whims rather than constitutional commands, she"s done an impressive job of hiding it all these years," Washington Post columnist Ruth Marcus writes, adding that the "amazing thing about the case against Sotomayor is how thin it is." She writes, "If Sotomayor is the judicial radical of conservative imaginings, certainly there ought to be something more in her paper trail."Marcus continues that an "examination of Sotomayor"s decisions shows a careful judge who tends to rule for the government over criminal defendants; who has been skeptical of most civil rights claims that have come before her; and who, to the extent that she has ruled on cases that touch on abortion, has come down against the abortion-rights side." According to Marcus, Sotomayor is "not apt to be David Souter in reverse -- a Democratic pick who turns out to be a close conservative." However, there also is "no evidence that she will be outside the liberal mainstream on the current court," Marcus writes. Marcus notes that Sotomayor "has ruled in favor of abortion protesters who claimed police used excessive force in removing them from outside a clinic," and she "refused to overturn the federal policy barring international family planning funds to organizations that perform or promote abortion," known as the "global gag rule." Marcus concludes, "Perhaps Sotomayor the radical has been biding her time, awaiting the day when the freedom of a Supreme Court seat would liberate her from precedent and moderation," but "the record suggests" that outcome is "unlikely" (Marcus, Washington Post, 6/3).
Endocrinology

Onset Therapeutics Launches HYLATOPIC™ Emollient Foam For Atopic Dermatitis

Onset Therapeutics, a specialty pharmaceutical company focused in dermatology, announced the FDA approval and commercial launch of HYLATOPIC™ Emollient Foam, a unique, non-steroidal prescription product indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis and radiation dermatitis. HYLATOPIC™ Emollient Foam is formulated to rapidly hydrate the stratum corneum, the top layer of the skin, and immediately provide a semi-permeable barrier that protects against irritants and excessive water loss through the epidermis. HYLATOPIC™ is clinically proven to rapidly increase skin hydration and reduce transepidermal water loss1, supporting the skin"s natural recovery from skin barrier dysfunction to optimize therapeutic outcomes. HYLATOPIC™ is safe and easy to spread over large areas and therefore is ideal for atopic dermatitis patients with disease coverage on greater than 10% body surface area (BSA). The Company"s recent market research with dermatologists indicates that 70% or more of their patients may have atopic dermatitis present on at least 10% of their body. Developed with the Company"s DELEVO™ Foam Technology, HYLATOPIC™ is cosmetically elegant, contains no drying alcohols, is absorbed rapidly, and leaves no oily or sticky residue. "We are very excited to be able to offer HYLATOPIC™ to our physicians and patients," states Michael Heffernan, President of Onset Therapeutics. "It is well known that skin barrier dysfunction is a fundamental problem in atopic dermatitis patients. HYLATOPIC"s 3-step approach to hydrate, protect and restore the natural skin barrier, combined with the aesthetic and safety elements which drive compliance, assists in helping our physicians achieve the best therapeutic outcomes." HYLATOPIC™ Emollient Foam is currently available through all major drug wholesalers. About Atopic Dermatitis Atopic dermatitis is a disease characterized by dry, cracked, itchy, and inflamed skin, often presenting on greater than 10% of the body surface area. It accounts for 10-20% of all Dermatology visits2 and affects approximately 3% of the US population2, 90% of whom develop symptoms by age 53. The compromised skin barrier in atopic dermatitis patients allows excessive water loss through the epidermal layer of the skin and penetration of potential allergens. About Onset Therapeutics Onset Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of dermatology products formulated with the Company"s innovative proprietary topical formulation technologies and unique delivery systems. The Company utilizes its novel DELEVO™ Foam Technology that is designed to deliver enhanced penetration of proven active ingredients in cosmetically elegant, hydrating formulations with the goal of enhancing patient compliance. For more information, please visit the company"s website at http://www.onsettx.com. References: 1. Data on File Collegium Pharmaceutical 2. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Available at: http://www.niams.nih.gov/hi/topics/dermatitis/index.html. 3. Rudikoff D, Lebwohl M. Atopic dermatitis. Lancet. 1998;351:1715-1721. Onset Therapeutics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):